Promising drug combo takes on tough childhood bone cancer

NCT ID NCT05830084

Ongoing Disease control Sponsor: Gustave Roussy, Cancer Campus, Grand Paris Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase study tests whether adding the targeted drug regorafenib to standard chemotherapy is safe for people with newly diagnosed, widespread Ewing sarcoma. The trial enrolls about 23 patients aged 2 to 49 whose cancer has spread beyond the lungs. The goal is to find a safe dose and see if the combination can improve outcomes for this hard-to-treat cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EWING SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Ewing sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EWING SARCOMA

Contacts and locations

Locations

CHU Bordeaux

Bordeaux, France
Centre Oscar Lambret

Lille, France
Gustave Roussy

Villejuif, Île-de-France Region, 94805, France
Institut Curie

Paris, France
Istituto Nazionale dei Tumori

Milan, 20133, Italy
Monash Children's Hospital

Clayton, Australia
Perth Children's Hospital

Perth, WA6009, Australia
Princess Máxima Center

Utrecht, 113, Netherlands
Queensland Children's Hospital

Brisbane, Australia
Rigshospitalet

Copenhagen, DK-2100, Denmark
Royal Children's Hospital

Parkville, Australia
Vall d'Hebron University Hospital

Barcelona, 119-12, Spain
centre Léon Bérard

Lyon, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.